

Supplementary Appendix

Asian subgroup analysis of patients in the phase 2 DeLLphi-301 study of tarlatamab for previously treated small cell lung cancer

Myung-Ju Ahn,¹ Byoung Chul Cho,² Kadoaki Ohashi,³ Hiroki Izumi,⁴ Jong-Seok Lee,⁵
Ji-Youn Han,⁶ Chi-Lu Chiang,⁷ Shuang Huang,⁸ Ali Hamidi,⁸ Sujoy Mukherjee,⁸
Krista Lin Xu,⁹ Hiraoki Akamatsu¹⁰

¹Hematology-Oncology Department, Samsung Medical Center (SMC), Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; ²Medical Oncology Department-501, ABMRC, Yonsei University, Seoul, Republic of Korea;

³Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan;

⁴Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan;

⁵Hematology/Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; ⁶Center for Lung Cancer, National Cancer Center-Graduate School of Cancer Science and Policy, Goyang, Republic of Korea; ⁷Department of Chest Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan;

⁸Amgen Inc., Thousand Oaks, CA, United States; ⁹Amgen Asia Pacific Pte. Ltd., Singapore; ¹⁰Internal Medicine III, Wakayama Medical University, Wakayama, Japan

Corresponding author: Hiroaki Akamatsu, MD, PhD, Internal Medicine III, Wakayama Medical University, 811-1, Kimiidera, Wakayama, Japan (hiroakiakamatsu@gmail.com)

List of investigators, sites, and IRBs

Country	Site	Investigator	IRB/IEC Name
Japan	National Cancer Center Hospital East	Hiroki Izumi	National Cancer Center IRB 2-J
Japan	Wakayama Medical University Hospital	Hiroaki Akamatsu	Wakayama Medical University IRB
Japan	Shizuoka Cancer Center	Kazushige Wakuda	Shizuoka Cancer Center IRB
Japan	Kindai University Hospital	Hidetoshi Hayashi	Kindai University Hospital IRB
Japan	Okayama University Hospital	Kadoaki Ohashi	IRB of Okayama University Hospital
Japan	Aichi Cancer Center Hospital	Yoshitsugu Horio	Aichi Cancer Center IRB
Japan	The Cancer Institute Hospital of Japanese Foundation for Cancer Research	Satoru Kitazono	The Cancer Institute Hospital of Japanese Foundation for Cancer Research IRB
Republic of Korea	Asan Medical Center	Sang-We Kim	Asan Medical Center IRB
Republic of Korea	Samsung Medical Center	Myung-Ju Ahn	Samsung Medical Center IRB
Republic of Korea	Yonsei University Health System Severance Hospital	Byoung Chul Cho	Yonsei University Health System Severance Hospital IRB
Republic of Korea	National Cancer Center	Ji-Youn Han	National Cancer Center IRB
Republic of Korea	Seoul National University Bundang Hospital	Jong-Seok Lee	Seoul National University Bundang Hospital- IRB
Taiwan	Taipei Veterans General Hospital	Hsu-Ching Huang Chi-Lu Chiang	Taipei Veterans General Hospital Institutional Review Board